title: [Corifollitropin alfa compared to daily FSH in controlled ovarian stimulation for oocyte donors].
abstract: OBJECTIVE
  To demonstrate that corifollitropin alfa is as effective as daily FSH in controlled ovarian stimulation of oocyte donors.
  
  
  METHODS
  From January 2013 to October 2015, 77 cycles controlled ovarian stimulation, derived from a continuous cohort of 77 oocyte donors, were analyzed. After synchronization by oestroprogestatif or estrogens, ovarian stimulation was started by corifollitropin alfa (Group corifollitropin alfa) or by daily FSH (Group daily FSH). In both groups, a GnRH antagonist was used for the prevention of premature surge of luteinizing hormone (LH). The induction of ovulation was induced by a GnRH agonist. The duration of treatment, estradiol rate, numbers of mature oocytes, fertilization rate, clinical and ongoing pregnancies rates were evaluated in the two groups.
  
  
  RESULTS
  There is no difference for the age, the markers of ovarian reserve and the duration of treatment. The average rate of estradiol on the eighth day of the stimulation is lower for the corifollitropin alfa (845±694.5 vs 1742±1177.3, P<0.001), there is no difference in the number of mature oocytes retrieved (14.4 vs 13.4, P=0.979), with a fertilization rate significantly higher in the corifollitropin alfa group (59.8% vs 49.3%, P<0.001). The rate of ongoing pregnancies is higher but without reaching significant difference in this same group (36.6% vs 26%, P=0.277).
  
  
  CONCLUSIONS
  As compared to daily FSH, corifollitropin alfa, in oocyte donors offers, advantages in terms of ease of use with identical efficiency.
authors.affiliation: Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Benchabane
authors.affiliation: Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; Institut Cochin, Inserm U1016, laboratoire d'immunologie, université Paris Descartes, Sorbonne Paris Cité, Paris, France; Institut Cochin, Inserm U1016, département de « génetique, développement et cancer », université Paris Descartes, Sorbonne Paris Cité, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Santulli
authors.affiliation: Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Maignien
authors.affiliation: Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Bourdon
authors.affiliation: Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: De Ziegler
authors.affiliation: Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France; Institut Cochin, Inserm U1016, laboratoire d'immunologie, université Paris Descartes, Sorbonne Paris Cité, Paris, France; Institut Cochin, Inserm U1016, département de « génetique, développement et cancer », université Paris Descartes, Sorbonne Paris Cité, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Chapron
authors.affiliation: Department of gynaecology obstetrics II and reproductive medicine Paris, faculté de médecine, hôpital universitaire Paris centre, université Paris Descartes, Sorbonne Paris Cité, centre hospitalier universitaire (CHU) Cochin, Assistance publique-Hôpitaux de Paris (AP-HP), Paris, France. Electronic address: vanessa.gayet@cch.aphp.fr.
authors.forename: V
authors.initials: V
authors.lastname: Gayet
mesh_terms: D000328:Adult; D005260:Female; D005307:Fertilization in Vitro / Q000706:statistics & numerical data; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage*; D043373:Follicle Stimulating Hormone, Human / Q000008:administration & dosage*; D006801:Humans; D018587:Oocyte Donation; D054315:Oocyte Retrieval; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate
chemical_list: D043373:Follicle Stimulating Hormone, Human; C437186:follicle stimulating hormone, human, with HCG C-terminal peptide; D005640:Follicle Stimulating Hormone
keywords: Corifollitropin alfa; Corifollitropine alpha; Donneuses ovocytes; Estradiol; FSH; Oocyte donors; Œstradiol